CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,187 enrolled
Drug / intervention
Favipiravir +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04600895
NCT04600895Phase 3Completed
CompareCT.gov

Favipiravir for Patients With Mild to Moderate Disease From Novel Coronavirus (COVID-19)

Appili Therapeutics Inc.·interventional·Posted Oct 23, 2020·Updated Mar 29, 2024

In Brief

A Phase 3 clinical trial evaluating Favipiravir and Placebo for Covid19. Completed, enrolled 1,187 participants across 38 sites in 3 countries.

Detailed Summary

Double-blinded, placebo control, randomized, phase-3 clinical trial to evaluate clinical efficacy of Favipiravir in patients with mild to moderate symptoms related to COVID-19 infection

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCovid19
CountriesBrazil, Mexico, United States
Collaborators--

Timeline

Phase 3CompletedFinished
202120222023202420252026
First PostedOct 23, 2020
Enrollment StartNov 30, 2020
Primary CompletionOct 20, 2021
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 5.7 years ago

Interventions

Favipiravirdrug

Favipiravir

Placebodrug

Placebo